Metabolic syndrome associated with hyperprolactinemia: a new indication for dopamine agonist treatment?

Endocrine. 2013 Oct;44(2):273-4. doi: 10.1007/s12020-013-9914-1. Epub 2013 Aug 22.

Authors

Ignacio Bernabeu¹, Felipe F Casanueva

Affiliation

¹ Endocrinology Division, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain.

PMID: 23975607
DOI: 10.1007/s12020-013-9914-1

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Agents, Hormonal / pharmacology*
Biomarkers / blood*
Carotid Intima-Media Thickness*
Ergolines / pharmacology*
Female
Humans
Inflammation / blood*
Insulin Resistance*
Pituitary Neoplasms / drug therapy*
Prolactinoma / drug therapy*

Substances

Antineoplastic Agents, Hormonal
Biomarkers
Ergolines